CJC-1295

A GHRH analog that boosts natural growth hormone production for body composition and recovery.

CJC-1295 DACCJC-1295 no DACModified GRF 1-29

CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to produce more growth hormone. It comes in two forms: with DAC (Drug Affinity Complex) for extended half-life, and without DAC (also called Modified GRF 1-29) for more natural pulsatile GH release. It is commonly paired with GHRP peptides like Ipamorelin for synergistic effects.

Key Benefits

Increased GH Production

Stimulates the pituitary to release growth hormone in a dose-dependent manner, elevating IGF-1 levels over sustained periods.

Improved Body Composition

Higher GH levels promote fat metabolism and lean muscle preservation, supporting body recomposition.

Enhanced Recovery

Elevated growth hormone accelerates tissue repair, reducing recovery time from training and injuries.

Better Sleep Quality

GH is primarily released during deep sleep. CJC-1295 may enhance the amplitude of natural nighttime GH pulses.

Anti-Aging Effects

Growth hormone supports collagen synthesis, skin elasticity, and overall cellular regeneration.

Bone Density Support

GH and IGF-1 play key roles in bone remodeling and maintaining mineral density.

Research Dosing Information

Common Dose

100-300 mcg per injection (no DAC) or 2 mg per week (with DAC)

Route

Subcutaneous injection

Frequency

1-3 times daily (no DAC) or 1-2 times weekly (with DAC)

Cycle Length

8-12 weeks, often cycled with breaks

Not FDA-approved. Best administered before bed or on an empty stomach to align with natural GH release patterns. Often combined with Ipamorelin. Avoid eating 30 minutes before and after dosing, as insulin blunts GH release.

Research Summary

CJC-1295 was originally developed by ConjuChem Biotechnologies. Clinical trials demonstrated sustained elevation of GH and IGF-1 levels with a favorable safety profile. The DAC version showed a half-life of approximately 8 days, allowing weekly dosing. Studies in healthy adults showed dose-dependent increases in GH (2-10 fold) and IGF-1 (1.5-3 fold) over baseline. Research continues into applications for growth hormone deficiency, sarcopenia, and metabolic disorders.

Safety Considerations

Not FDA-approved for any medical use.
Common side effects include flushing, headache, and injection site reactions.
May cause water retention and joint pain at higher doses.
Contraindicated in individuals with active malignancies due to GH/IGF-1 promotion.
Should not be used without medical supervision in individuals with diabetes, as GH affects glucose metabolism.

Frequently Asked Questions

What is the difference between CJC-1295 with and without DAC?

The DAC (Drug Affinity Complex) version has an extended half-life of ~8 days, providing sustained GH elevation. Without DAC (Modified GRF 1-29), the half-life is ~30 minutes, creating a more natural pulsatile GH release pattern.

Why combine CJC-1295 with Ipamorelin?

CJC-1295 stimulates GH release via GHRH receptors while Ipamorelin stimulates via ghrelin receptors. Together they create a synergistic amplification of GH release that exceeds either peptide alone.

When should I take CJC-1295?

Research protocols typically administer before bed on an empty stomach to amplify the natural nighttime GH surge. Avoid food 30 minutes before and after, as insulin inhibits GH release.